Actively Recruiting
Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care
Led by Shanghai 6th People's Hospital · Updated on 2025-03-04
80
Participants Needed
1
Research Sites
132 weeks
Total Duration
On this page
Sponsors
S
Shanghai 6th People's Hospital
Lead Sponsor
S
Shanghai Jiao Tong University School of Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
Enhanced recovery after surgery (ERAS) is a strategy of perioperative management aimed to accelerate the rehabilitation of patients through various optimized perioperative managements as well as ongoing adherence to a patient-focused, multidisciplinary, and multimodal approach. Alleviating the injury and stress caused by surgery or disease is the core principle of ERAS, which has been shown to reduce complication rates after surgery, promote patient recovery, decrease hospital length of stay and reduce costs. ERAS has been widely applied in many surgical perioperative fields, and it has achieved remarkable effects. However, there are few applications of ERAS in neurosurgery, especially in clinical trials of neurocritical care patients. Therefore, the investigators attempt to conduct the study of ERAS in neurosurgical intensive patients using a series of optimized perioperative managements that have been verified to be effective by evidence-based medicine, and to evaluate the safety and effectiveness of ERAS in neurocritical care. The aim of this study is to explore the most suitable ERAS protocols to accelerate the postoperative rehabilitation process of neurocritical care patients, and to provide more evidence-based medicine for the effectiveness and safety of ERAS in neurosurgery.
CONDITIONS
Official Title
Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years old
- Moderate or severe acute traumatic brain injury or cerebrovascular disease requiring neurosurgical intensive care
- Hospitalization time of at least 1 week
- Guardian able to understand and actively cooperate
- Guardian signs informed consent form
You will not qualify if you...
- Patients undergoing non-surgical treatment
- Brain death diagnosis within first 24 hours after NICU admission
- Patients receiving cardiopulmonary resuscitation, maintenance dialysis, with end-stage tumors or disseminated cancer
- Patients who withdraw treatment during hospitalization or are discharged automatically
- Patients undergoing unplanned secondary surgery during the study
- Individuals who cannot be followed up during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai 6th People's Hospital
Shanghai, China, 200233
Actively Recruiting
Research Team
H
Hao Chen, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here